-
NVDA
NVIDIA
-
#1
-
AAPL
Apple
-
#2
-
MU
Micron Technology
-
#3
-
MSFT
Microsoft
-
#4
-
AMZN
Amazon.com
-
#5
-
AVGO
Broadcom
-
#6
-
PLTR
Palantir Technologies
-
#7

Zacks.com Most Recent Articles
Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates
Tale of the Tape
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of -75.51% and -23.60%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
STAANegative Net Change COONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ross Stores (ROST) Tops Q4 Earnings and Revenue Estimates
Tale of the Tape
by Zacks Equity Research
Ross Stores (ROST) delivered earnings and revenue surprises of +6.61% and +3.69%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
ROSTNegative Net Change DGPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Tale of the Tape
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
RIGLNegative Net Change VVOSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Buy Broadcom Stock as Q1 Results Approach or Choose Nvidia Instead?
Investment Ideas
by Shaun Pruitt
Broadcom has a unique niche as it relates to AI chips and silicon networking, but Nvidia has the broader reach and the same hyperscale customers.
NVDANegative Net Change AVGONegative Net Change AMZNPositive Net Change MSFTPositive Net Change GOOGLNegative Net Change
artificial-intelligence earnings electronics investing large-cap semiconductor tech-stocks
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Tale of the Tape
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -11.71% and -49.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ARCTNegative Net Change STRONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Top Research Reports for Broadcom, AT&T & Vertex Pharmaceuticals
Research Daily
by Mark Vickery
Broadcom rides AI chip momentum with VMware gains, while AT&T and Vertex navigate growth plans and key headwinds in latest Zacks reports.
TPositive Net Change BKNegative Net Change HSYNegative Net Change VRTXNegative Net Change AVGONegative Net Change INTGNegative Net Change MRSHNegative Net Change
communications medical reit semiconductor
Best "Strong Buy" Stocks to Buy Now in March
Screen of the Week
by Benjamin Rains
How investors can find the best Zacks Rank #1 (Strong Buy) stocks out of a group of over 200 highly-ranked companies to consider buying right now.
GOLDNegative Net Change
gold
Can These Beaten Down Stocks Turn Things Around? NKE, ADBE
Investment Ideas
by Derek Lewis
NIKE has struggled to capture what its consumers want, with a loss of shelf space also reducing its presence to the consumer. Adobe is at risk of considerable disruption from the broader AI outlook. Can upcoming earnings releases this month help turn sentiment around?
NKENegative Net Change ADBEPositive Net Change
apparel artificial-intelligence earnings software tech-stocks
Stocks in Turmoil, but Attractive Setups Emerge (META, GOOGL, AMZN)
Investment Ideas
by Ethan Feller
The Magnificent 7 stocks, most notably Meta Platforms, Alphabet and Amazon stand out as especially compelling opportunities amid this pullback
AMZNPositive Net Change GOOGLNegative Net Change MAGSNegative Net Change METAPositive Net Change
artificial-intelligence magnificent-7
Zacks Initiates Coverage of MUEL With Neutral Recommendation
Microcap Article
by Zacks Equity Research
Discover why Zacks, the first on Wall Street to initiate coverage, rates MUEL as "Neutral." Explore how Paul Mueller's surging backlog and pharma-driven growth are reshaping its revenue outlook amid key execution risks.
MUELNegative Net Change
industrial-products